Pfizer Will Monitor Off-Label Drug Use And Report To IG Under Neurontin Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
Corporate integrity agreement will be carefully studied in pharmaceutical industry given uncertainties surrounding off-label promotion rules. Pfizer agrees to establish clear policies and keep close tabs on off-label use – but the agreement does not define prohibited or permitted activities.